Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Editas Medicine (EDIT) over the last 9 years, with Q3 2025 value amounting to $4.7 million.

  • Editas Medicine's Other Non-Current Liabilities rose 4288.33% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 4288.33%. This contributed to the annual value of $3.1 million for FY2024, which is 7066.67% up from last year.
  • Editas Medicine's Other Non-Current Liabilities amounted to $4.7 million in Q3 2025, which was up 4288.33% from $4.6 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Other Non-Current Liabilities registered a high of $6.4 million during Q1 2025, and its lowest value of $1.8 million during Q4 2023.
  • Its 3-year average for Other Non-Current Liabilities is $3.9 million, with a median of $3.6 million in 2024.
  • Over the last 5 years, Editas Medicine's Other Non-Current Liabilities had its largest YoY gain of 8321.34% in 2025, and its largest YoY loss of 2186.84% in 2025.
  • Over the past 3 years, Editas Medicine's Other Non-Current Liabilities (Quarter) stood at $1.8 million in 2023, then surged by 70.67% to $3.1 million in 2024, then surged by 52.6% to $4.7 million in 2025.
  • Its Other Non-Current Liabilities was $4.7 million in Q3 2025, compared to $4.6 million in Q2 2025 and $6.4 million in Q1 2025.